New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
05:55 EDTALPMF, AVEOAveo, Astellas to end collaboration, license agreement for tivozanib
AVEO Oncology (AVEO) and Astellas Pharma (ALPMF) announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib. Tivozanib is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors. Astellas has exercised its right to terminate the agreement signed in 2011 for strategic reasons, based on the clinical status of the three indications studied. Additionally, the companies agreed to discontinue the ongoing Phase 2 BATON study in patients with colorectal cancer. The termination of the collaboration will be effective August 11, 2014 at which time tivozanib rights will be returned to AVEO. In accordance with the collaboration and license agreement, committed development expenses will be shared equally.
News For AVEO;ALPMF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:14 EDTAVEOAveo Pharmaceuticals to host conference call
Conference call to discuss presentation of final results and biomarker analysis from Phase 2 study of Tivozanib in Patients with Advanced Colorectal Cancer will be held on March 6 at 8 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use